Spantide acetate

TargetMol
Product Code: TAR-T20413L
Supplier: TargetMol
CodeSizePrice
TAR-T20413L-1mg1mg£176.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-5mg5mg£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-10mg10mg£515.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-1mL1 mL * 10 mM (in DMSO)£702.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-25mg25mg£788.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-50mg50mg£1,050.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-100mg100mg£1,396.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20413L-500mg500mg£2,705.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Spantide acetate is a selective antagonist of NK1 receptor with Kis of 230 nM and 8150 nM for NK1 and NK2.
CAS:
T20413L
Formula:
C77H112N20O15
Molecular Weight:
1557.84
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.98
SMILES:
CC(C[C@H](NC([C@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H]1CCCN1C([C@H](CCCCN)NC([C@@H]2CCCN2C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CC3=CNC4=CC=CC=C43)=O)CC5=CC=CC=C5)=O)CC6=CNC7=CC=CC=C76)=O)C(N[C@@H](C(N)=O)CC(C)C)=O)C.CC(O)=O
Target:
Neurokinin receptor

References

1. M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34(1):13-8. 2. Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):797-807. 3. J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108(3):793-800.